Relay Therapeutics is a biotechnology company engaged in developing precision medicine evaluating the movement of proteins (protein motion) with the help of artificial intelligence (AI) and a supercomputer-powered platform. The company’s initial focus is on precision oncology, but it believes its platform will have applications in other areas of precision medicine such as genetic diseases. Its platform, Dynamo, uses a custom-built supercomputer engineered by David E. Shaw, one of the company’s co-founders. Dynamo can be mainly used in target identification, lead generation, and lead optimization.

The company has three drug candidates in its wholly-owned pipeline: 1) RLY-1971, which acts as a protein inhibitor in solid tumors, and is at the Phase I stage of clinical trials; 2) RLY-4008, which is designed to inhibit fibroblast growth factor receptor 2. The company intends to bring this to clinical trials by the end of 2020; and 3) RLY-PI3K1047, which targets cancer-associated variants of phosphoinositide 3-kinase alpha and is currently at the preclinical stage. In addition to these, Relay also has five programs at the discovery stage across precision oncology and genetic diseases. The company went public in July 2020, raising USD 425 million, one of biotech’s largest IPOs of 2020. The company has not generated any revenue from product sales or any other sources and does not expect to generate revenue from product sales in the near future. It recorded net losses of USD 75.3 million in 2019, increasing 54.3% from 2018.